Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Artiman Ventures

Artiman is a venture capital company founded in 2 and based in Palo Alto California. The firm is currently making investments out of its fourth $2 million fund. The firm makes seed and venture investments into firms ranging from a few hundred thousand to $5 million depending on the stage and financial requirements of the company. The firm has a preference for companies based in Silicon Valley but will consider opportunities globally and looks to make around 5 investments per year.
Website:
www.artiman.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Akhil Saklecha
Managing Director 

Astia Angels

Astia is an organization whose mission is to provide women-led startups access to capital resources and executive leadership. Astia was founded in 2013 and is based in San Francisco California with additional offices in New York New York and London United Kingdom. Astia typically provides access to capital to women-led life science companies through two programs: Astia Venture Lunches and Astia Angels and is in the process of developing a third program: Astia Fund. Companies that apply to Astia Venture Lunches will be vetted by Astia?s Expert Sift process. The selected companies are invited to present to a room of accredited investors: VCs and angels. Companies applying to Astia are also considered by Astia Angels and the investments from Astia Angels are typically under $1 million. Astia is stage agnostic though companies applying should be able to show traction and proof of concept. Companies can be global and must have at least one woman in a leadership position of significant influence and holding equity.
Website:
www.drexler.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Karen Drexler
Founder 
Sharon Vosmek
CEO 
Sara Frankel
Member 

ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Website:
www.atemcap.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baird Venture Partners

Baird Venture Partners is the venture and expansion capital arm of Robert W. Baird & Co. The Baird Venture Partners team is based in Chicago Illinois and has around $27 million in total assets under management. In 214 Baird closed a fourth venture capital fund at $185 million. The firm is currently seeking opportunities in the life science sector and while Baird has no strict timeline to make investments the group would invest in a new firm within the next 6-9 months if a compelling opportunity was identified. The firm?s equity investments range from $3-1 million but are typically in the $8-1 million range.The firm will only consider investment into US based firms.
Website:
www.rwbaird.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Momei Qu
Senior Associate 

Band of Angels

The Band of Angels is a funding organization that was founded in 1994 and it is based in Silicon Valley California. The organization typically provides capital to companies through three programs: The Band of Angels Acorn Fund and The Band of Angels Venture Fund. The group focuses on seed and Series A stage high-tech companies across several industries including life science space. The Band of Angels generally makes investments ranging from $3K to $75k but it often leads a syndication of $2-3million. Acorn Fund which is The Band?s third side fund and was founded in 29 generally makes investments ranging from $1k to $75k. The Band of Angels Venture Fund is a $5 million venture fund which raised in 1999 by The Band of Angels. Initial investment sizes of the fund are typically $3 and can go up to $2.5 million. The Band generally makes around 1 -2 investments per year. The group focuses on companies based in Silicon Valley but it will consider selective opportunities in Los Angles and San Diego areas. The group's portfolio includes biotechnology and medical device companies working with oncology and muscle recovery.
Website:
www.tosk.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Brian Frenzel
Member 
Michael Bates
Member, Board of Directors 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Priyanka Rohatgi
Director 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Website:
www.bd.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Albert Lauritano
Director Strategic Technology Partnerships 

Bioarray Therapeutics Inc. United States

BIOARRAY is a biotech company located at the Science park in New Haven. BIOARRAY is customizing treatments for patients to cure breast cancer the first time. BIOARRAY’s lead breast cancer test has been shown to reduce ineffective treatments by over 50% in proof of concept studies. BIOARRAY is a recipient of Avon Foundation and Connecticut Innovations funds. BIOARRAY is a MassChallenge Accelerator Winner.

Website:
http://bioarray.us/
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview

In contrast to most studies that focus on the unhealthy cancer patient populations, BIOARRAY studies cancer in reverse by using genes in healthy cell organization to identify cancer markers. These biomarkers work like surveillance cameras watching how a particular breast cancer will behave when treated with chemotherapy. By measuring the mRNA expression levels of these biomarkers, Bioarray diagnostic tests significantly increase the accuracy of predicted chemo-response rates.

Alliance & Collaborations
Avon Foundation, Connecticut Innovations
Supporting Metrics or Evidence

BIOARRAY's lead test distinguishes itself by addressing a vital question at the beginning of basic chemotherapeutic treatment for 75% of diagnosed breast cancer patients who currently have a 24% response rate. BIOARRAY's test clinical proof of concept studies showed:

55% reduction in ineffective chemo

68% improvement in response rate

42% of patients classified as non-responders up front

Current Financing Needs

The company is raising its Series A round of financing to achieve key milestones to take the lead test to early adoption.

Current Timeline

BIOARRAY has developed a business plan whereas the Bioarray diagnostic uses commercially-available gene-expression platforms such as PCR for its lab analysis. BIOARRAY will engage licensees and distributors to access the global market. BIOARRAY will hold closely the proprietary algorithms at the heart of the diagnostic in a cloud-based information platform. BIOARRAY's lead test is in a position to go to market within 2 years.

Current Investors

Grant: Avon Foundation – first of its kind from Avon

Equity: Connecticut Innovations and Angels

IP Status

BIOARRAY intellectual property includes methods, algorithms and biomarkers. BIOARRAY strategy to protect its intellectual property is a combination of trade secrets and patents. The company is growing a patent portfolio of US and international patents that is exclusively owned by BIOARRAY and is not subject to licensing or royalty obligations.

Recent Milestones

  1. Performed clinical proof of concept with I-SPY 1 clinical trial
  2. Data gathered (and ready to complete analysis) for I-SPY 2 trial
  3. Built cloud-based interactive information platform and interactive portal
  4. Built laboratory infrastructure
  5. Developed IP strategy comprising know-how and patents (internationally filed)
Management Team Highlights

CEO Marcia Fournier has over a decade of experience in oncology at leading Institutions in the US. Non-executive chairman Michal Preminger and Board Directors Una Ryan and Henry Kay have extensive experience in management, financing, acquisitions, and diagnostics. The Company also has a team of active business advisors with experience in business development, acquisitions and venture capital.

Marcia Fournier
Marcia Fournier
LinkedIn logo CEO 
BIO

Marcia, a molecular biologist, came to the United States from Brazil about 15 years ago. Marcia is trained in genetics with 10+ years of experience in cancer research. She most recently held a position at GlaxoSmithKline, Oncology Center of Excellence for Drug Discovery. Marcia’s work as a doctoral fellow at the Dana-Farber Institute and postdoctoral fellow at UC Berkeley led to seminal publications on biomarker discovery.

Rana Gupta
Rana Gupta
LinkedIn logo Business Advisor 
BIO

Rana K, Gupta is trained as a businessman (not a techie), Rana has worked in several industries (pharma, consulting, VC), but he comes to BIOARRAY as a result of having invested in, run, and ultimately sold diagnostic company HistoRx to Novartis.

 

BioScience Managers Australia

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Website:
http://www.biosciencemanagers.com/
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jeremy Curnock Cook
Managing Director 
Amanda Gillon
Investment Analyst 
Matt McNamara
CIO 

Breakout Labs

Breakout Labs was founded by the Thiel Foundation in 211 and is based in San Francisco CA. Breakout Labs provides seed grants of $35 to 8-1 early stage companies per year. Companies must reach specific milestones in order to receive installments of the grant. Breakout Labs grants are in the form of a convertible note that if the company raises a Series A round will convert based on the Series A valuation, however if the company fails before raising a Series A round no debt will be due. Additionally when a portfolio company becomes revenue-generating or is acquired Breakout Labs receives a 3% royalty payment capped at 3x the value of the grant. Breakout Labs funds companies throughout the USA.
Website:
www.thielfoundation.org
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Lindy Fishburne
Executive Director 
Michelle Kim-Danely
Portfolio Manager